S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NYSE:ABT

Abbott Laboratories (ABT) Price Target & Analyst Ratings

$96.85
-1.27 (-1.29%)
(As of 09/29/2023 ET)
Compare
Today's Range
$96.48
$98.51
50-Day Range
$95.55
$114.62
52-Week Range
$93.25
$115.83
Volume
5.15 million shs
Average Volume
4.15 million shs
Market Capitalization
$168.07 billion
P/E Ratio
33.05
Dividend Yield
2.11%
Price Target
$120.82

Abbott Laboratories Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 15 Analyst Ratings

Consensus Analyst Price Target

$120.82
24.75% Upside
High Prediction$136.00
Average Prediction$120.82
Low Prediction$102.00
TypeCurrent
10/1/22 to 10/1/23
1 Month Ago
9/1/22 to 9/1/23
3 Months Ago
7/3/22 to 7/3/23
1 Year Ago
10/1/21 to 10/1/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
11 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$120.82$120.82$121.26$132.46
Predicted Upside24.75% Upside12.68% Upside13.50% Upside14.46% Upside
Get Abbott Laboratories Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


ABT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside24.75% Upside869.81% Upside698.21% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/24/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$127.00 ➝ $132.00+15.50%
7/21/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$112.00+0.17%
7/21/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$110.00 ➝ $115.00+2.85%
7/21/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Peer Perform
4/20/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$116.00 ➝ $123.00+11.31%
4/20/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$132.00 ➝ $133.00+19.44%
4/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$118.00 ➝ $122.00+9.56%
4/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$117.00 ➝ $130.00+15.77%
4/19/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$125.00 ➝ $130.00+15.77%
4/17/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$125.00 ➝ $130.00+25.05%
4/5/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$140.00 ➝ $136.00+32.30%
3/31/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$90.00 ➝ $102.00+2.95%
3/30/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $115.00+16.61%
1/26/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$110.00 ➝ $125.00+12.35%
10/20/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$110.00+15.53%
10/20/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$132.00 ➝ $126.00+28.43%
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$110.00+8.11%
(Data available from 10/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABT Price Target - Frequently Asked Questions

What is Abbott Laboratories's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Abbott Laboratories stock is Moderate Buy based on the current 5 hold ratings and 10 buy ratings for ABT. The average twelve-month price prediction for Abbott Laboratories is $120.82 with a high price target of $136.00 and a low price target of $102.00. Learn more on ABT's analyst rating history.

Do Wall Street analysts like Abbott Laboratories more than its competitors?

Analysts like Abbott Laboratories more than other Medical companies. The consensus rating score for Abbott Laboratories is 2.67 while the average consensus rating score for medical companies is 2.66. Learn more on how ABT compares to other companies.

Is Abbott Laboratories being upgraded by Wall Street analysts?

Over the previous 90 days, Abbott Laboratories's stock had 1 upgrade by analysts.

Does Abbott Laboratories's stock price have much upside?

According to analysts, Abbott Laboratories's stock has a predicted upside of 12.68% based on their 12-month price targets.

What analysts cover Abbott Laboratories?

Abbott Laboratories has been rated by Barclays, Mizuho, Morgan Stanley, and Wolfe Research in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ABT) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -